Working… Menu

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients (AELIX-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04364035
Recruitment Status : Active, not recruiting
First Posted : April 27, 2020
Last Update Posted : August 2, 2021
Gilead Sciences
Information provided by (Responsible Party):
Aelix Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 15, 2022
Estimated Study Completion Date : December 23, 2022